Results 131 to 140 of about 1,079 (142)

Monomeric C-Reactive Protein in Atherosclerotic Cardiovascular Disease: Advances and Perspectives

International Journal of Molecular Sciences, 2023
Ivan Melnikov, Sergey Kozlov, Yuliya Avtaeva   +2 more
exaly  

Targeted downregulation of mCRPs (CD46, CD55, and CD59) specifically sensitizes transferrin-receptor (CD71) high expressing malignant cells to complement attack

Molecular Immunology, 2011
M.C. Cinci, S. Mamidi, M. Kirschfink
openaire   +1 more source

AMD associated Y402H polymorphism affects binding of the complement regulator mCRP and results in an altered complement control on necrotic ARPE-19 cells

Molecular Immunology, 2009
Nadine Lauer, Michael Mihlan, Bernhard H.F. Weber, Frank Sühnel, Claudia v. Strachwitz, Andrea Hartmann, Peter F. Zipfel, Christine Skerka   +7 more
openaire   +1 more source

Multimeric FHR4 immunoconjugates promote efficient activation of CAP on Her2 tumour cells, further controlled by overexpressed mCRPs, limiting MAC formation and CDC

Molecular Immunology, 2017
Jean-Marc Plesseria, Charlène Verschueren, Gilles Iserentant, Jacques H.M. Cohen, Carole Devaux, Xavier Dervillez   +5 more
openaire   +1 more source

Monomeric C-Reactive Protein Aggravates Secondary Degeneration after Intracerebral Haemorrhagic Stroke and May Function as a Sensor for Systemic Inflammation

Journal of Clinical Medicine, 2020
Mario DI NAPOLI, , Coral Sanfeliu
exaly  

Cell membranes and liposomes dissociate C‐reactive protein (CRP) to form a new, biologically active structural intermediate: mCRP m

FASEB Journal, 2007
Li Zhu, Shang-Rong Ji
exaly  

The influences of ApoE isoforms on endothelial adherens junctions and actin cytoskeleton responding to mCRP

Angiogenesis
Thor Stein, Jingyan Han, Zhengrong Zhang   +2 more
exaly  

The anti-mCRP199–206 antibodies aggravate tubulointerstitial lesions in lupus nephritis

Clinical Immunology
Mo Yuan, Ying Tan, Ming-Hui Zhao
exaly  

mCRP as a Biomarker of ANCA ‐Associated Vasculitis

International Journal of Rheumatic Diseases
Masaaki Fujita
exaly  

Spezifisches „Targeting“ von Tumorzellen: Zielgerichtete Expressionshemmung humaner membranständiger Komplement-regulatoren (mCRP) zur Überwindung der Komplementresistenz von CD71 hoch-exprimierenden Tumorzellen

2015
openaire   +1 more source